Basit öğe kaydını göster

dc.contributor.authorUema, Deise
dc.contributor.authorBoegemann, Martin
dc.contributor.authorKrissel, Heiko
dc.contributor.authorChen, Huanyu
dc.contributor.authorWagner, Volker Jean
dc.contributor.authorFizazi, Karim
dc.contributor.authorGonzalez del Alba, Aranzazu
dc.contributor.authorMustafa, Ozguroglu
dc.contributor.authorSkoneczna, Iwona Anna
dc.date.accessioned2021-12-10T13:01:34Z
dc.date.available2021-12-10T13:01:34Z
dc.date.issued2021
dc.identifier.citationFizazi K., Gonzalez del Alba A., Mustafa O., Skoneczna I. A. , Krissel H., Uema D., Chen H., Wagner V. J. , Boegemann M., "Radium-223 (Ra-223) versus novel antihormone therapy (NAH) for progressive metastatic castration-resistant prostate cancer (mCRPC) after 1 line of NAH: RADIANT, an international phase 4, randomized, open-label study.", JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.15, 2021
dc.identifier.issn0732-183X
dc.identifier.othervv_1032021
dc.identifier.otherav_e93562aa-58c7-43ce-ab3d-c17ad0eb4da8
dc.identifier.urihttp://hdl.handle.net/20.500.12627/175250
dc.identifier.urihttps://doi.org/10.1200/jco.2021.39.15_suppl.tps5093
dc.language.isoeng
dc.subjectOnkoloji
dc.subjectOncology
dc.subjectHealth Sciences
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.titleRadium-223 (Ra-223) versus novel antihormone therapy (NAH) for progressive metastatic castration-resistant prostate cancer (mCRPC) after 1 line of NAH: RADIANT, an international phase 4, randomized, open-label study.
dc.typeMakale
dc.relation.journalJOURNAL OF CLINICAL ONCOLOGY
dc.contributor.department, ,
dc.identifier.volume39
dc.identifier.issue15
dc.contributor.firstauthorID2769941


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster